For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240513:nRSM2093Oa&default-theme=true
RNS Number : 2093O GSK PLC 13 May 2024
BLOCK LISTING SIX MONTHLY RETURN
Date: 13 May 2024
Name of applicant: GSK plc
Name of scheme: GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan
Period of return: From: 1 November 2023 To: 30 April 2024
Balance of unallotted securities under scheme(s) from previous return: 271,307
Plus: The amount by which the block scheme(s) has been increased since the 0
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period 155,789
(see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 115,518
Name of applicant: GSK plc
Name of scheme: GlaxoSmithKline plc Share Save Plan 2012
Period of return: From: 1 November 2023 To: 30 April 2024
Balance of unallotted securities under scheme(s) from previous return: 506,598
Plus: The amount by which the block scheme(s) has been increased since the 2,000,000
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period 1,833,574
(see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 673,024
Name of applicant: GSK plc
Name of scheme: GlaxoSmithKline plc Share Save Plan 2022
Period of return: From: 1 November 2023 To: 30 April 2024
Balance of unallotted securities under scheme(s) from previous return: 999,109
Plus: The amount by which the block scheme(s) has been increased since the 0
date of the last return (if any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) during period 3,852
(see LR3.5.7G):
Equals: Balance under scheme(s) not yet issued/allotted at end of period: 995,257
Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END BLRLXLFFZELBBBZ